Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

atazanavir/ritonavir

A fixed combination of atazanavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, and ritonavir, a cytochrome P450 3A4 (CYP3A4) inhibitor, that may be used to treat HIV-1 infection. Upon oral administration of atazanavir/ritonavir, atazanavir selectively binds to the active site of HIV-1 protease and inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions. Ritonavir inhibits CYP3A4, thereby limiting the metabolism of atazanavir, which is a CYP3A4 substrate, and increasing its systemic exposure. This leads to an increased concentration and half-life of atazanavir as compared to the administration of atazanavir without ritonavir.
Synonym:atazanavir-ritonavir
ritonavir/atazanavir
Foreign brand name:Anzavir-R
Search NCI's Drug Dictionary